ADAP Adaptimmune Therapeutics Quarterly EPS earnings growth

Adaptimmune is a British leader in TCR-T bioengineering for solid tumors with robust R&D potential. Assessing quarterly EPS growth helps filter speculative noise from actual profit dynamics, with the indicator currently standing at 0.00. The company's prospects rely on the unique FDA approval of Tecelra and complex manufacturing logistics, which, combined with immune programming, establish new oncological standards.

Adaptimmune Therapeutics (ADAP) Year-over-year earnings per share growth for the last twelve months: for the period 07/04/2022 - 11/15/2025

Adaptimmune (ADAP) - metric breakdowns and financial figures

- share price and expert price forecast:

Stock Price adaptimmune.com|ADAP - Consensus Target

- market capitalization data:

Market Capitalization Adaptimmune|ADAP - Total Enterprise Value

- balance sheet net asset value indicators:

Net Assets per Single Share Adaptimmune Therapeutics|ADAP - Company Book Value|Market Value to Book Value Ratio adaptimmune.com|ADAP - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and market multiples details:

ADAP - Company Net Income|Future Profit Adaptimmune|ADAP - Company Value to Net Income|Projected Price to Earnings adaptimmune.com|ADAP - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Adaptimmune|ADAP - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Adaptimmune Therapeutics|ADAP - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months adaptimmune.com|ADAP - Earnings per share increase in current year|Earnings growth forecast for next year Adaptimmune

Fundamental company analysis:Adaptimmune Therapeutics plc - ADAP

The resilience of Adaptimmune (ADAP) depends on the successful market launch of Tecelra and the scaling of the SPEAR platform, which is directly reflected in the dynamics of the quarterly EPS growth marker. This indicator measures the percentage change in net earnings per share relative to the previous quarter, allowing investors to assess the monetization speed of biotech production and adjust the asset's valuation should profit growth rates deviate from expectations.

Analysis of competing companies

LEGN: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Sana Biotechnology Inc|AUTL (Autolus Pharma) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Allogene Corp ALLO|Year-over-year earnings per share growth for the last twelve months Cartesian Therapeutics (RNAC)|Year-over-year earnings per share growth for the last twelve months CLLS (cellectis.com)|Year-over-year earnings per share growth for the last twelve months Caribou Biosciences, Inc. CRBU|Instil Bio Inc. - Year-over-year earnings per share growth for the last twelve months|GNTA: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months IPSC (Century Therapeutics)|JSPR: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Senti Biosciences SNTI|CERO (CERo Therapeutics Holdings, Inc.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Alaunos TCRT|Year-over-year earnings per share growth for the last twelve months Achilles Therapeutics (ACHL)|CARGO Therapeutics, Inc - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth PSTX (Poseida Therapeutics)|2seventybio.com (TSVT) - Earnings per share growth in annualized terms for the last twelve months|GRCL: Year-over-year net earnings per share growth for the last 12 months